NL-OMON36500已完成不适用
Double-blind, placebo-controlled, multiple ascending-dose study to investigate the safety and tolerability of AZ01 in healthy volunteers. - AZ01 (PEGYLATED INTERFERON BETA)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy men and women, 18 and 45 years of age, inclusive, BMI 18 and 30 kg/m2, max. 5 cigarettes smoking per day.
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects with Established Parkinson*s DiseasePDParkinson's diseaseNL-OMON48411Alexza Pharmaceuticals Inc.32
进行中（未招募）
不适用
Double blind, placebo controlled, escalating single-dose, pilot study to assess the safety of THR-18 when administered to patients suffering acute ischemic stroke and treated with tPAAcute isquemic strokeMedDRA version: 14.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-005317-37-ESThrombotech Ltd.22
进行中（未招募）
1 期
Double blind, placebo controlled, escalating single-dose, pilot study to assess the safety of THR-18 when administered to patients suffering acute ischemic stroke and treated with tPAAcute ischemic strokeMedDRA version: 14.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-005317-37-ATThrombotech Ltd.22
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled, multinational, multi-centre, Phase IIb / III study of the efficacy and safety of three doses of sublingual immunotherapy (SLIT) administered as tablets once daily to patients suffering from grass pollen rhinoconjunctivitisEUCTR2004-001910-15-CZStallergenes S.A.631
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitisPatients with active incomplete microscopic colitisMedDRA version: 14.1Level: PTClassification code 10056979Term: Colitis microscopicSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-001912-31-ESDr. Falk Pharma GmbH106